Impact of KRAS Mutations on Management of Colorectal Carcinoma

<table>The current treatment paradigm for patients with metastatic colorectal cancer who are appropriate for intensive therapy [<a href="/journals/pri/2011/219309/#B11">9</a>].  *For patients with KRAS WT gene only.  CapeOX: capecitabine + oxaliplatin.</table>

Pathology Research International

fig2

Figure 2

Figure 2: Impact of KRAS Mutations on Management of Colorectal Carcinoma 